[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wetamd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wetamd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100639516","phase-2-phase-2a-study-to-evaluate-the-efficacy-and-safety-of-scai-005-ophthalmic-solution-in-subjects-with-neovascular-age-related-macular-degeneration-100639516",false,"NCT07607561","Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration","A Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter, Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration","Inclusion Criteria:\n\n1. Adults aged 50 years or older\n2. Subjects who were diagnosed with nAMD in the study eye within 3 years prior to the Screening Visit, who demonstrated a treatment response to at least 3 repeated intravitreal injections of anti-VEGF IVT for nAMD, and whose last anti-VEGF IVT administration was more than 12 weeks prior to the planned date of the first administration of the investigational product.\n3. Active MNV secondary to nAMD with a subfoveal component related to the MNV activity in the study eye as assessed by FA (evidence of leakage) or SD-OCT (presence of fluid) at screening\n4. CST ≤ 450 μm at screening\n5. BCVA ETDRS letter score of 80 letters to 25 letters in the study eye as measured by the ETDRS visual acuity chart at screening\n\nExclusion Criteria:\n\n1. Subjects with choroidal neovascularization in the study eye due to causes other than nAMD (however, polypoidal choroidal vasculopathy (PCV) can be enrolled)\n2. Presence of scarring, fibrosis, or atrophy involving the fovea in the study eye at Screening\n3. Subjects who have a hemorrhage in the subfoveal region of the study eye and in whom the subretinal hemorrhage area is ≥ 1 optic disk area\n4. History of glaucoma surgery, vitrectomy, submacular surgery, or macular laser treatment (e.g., photodynamic therapy \\[PDT\\], laser photocoagulation, etc.) in the study eye\n5. Subjects with vitreous hemorrhage in the study eye\n6. History of ocular treatment (except for anti-VEGF IVT therapy), systemic treatment, or surgical intervention for the treatment of neovascular age-related macular degeneration (nAMD) in the study eye\n7. Administration of intraocular, periocular, or intravitreal (IVT) steroid injection in the study eye within 24 weeks prior to Screening\n8. Presence of diabetic retinopathy, diabetic macular edema, or other vascular diseases affecting the retina, other than neovascular age-related macular degeneration (nAMD), in either eye\n9. History of endophthalmitis or idiopathic or autoimmune-related uveitis in either eye\n10. Subjects with active macular neovascularization identified in the fellow eye at Screening","ALL","50 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration.\n\nThe purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).",[26,27],"wetAMD","Age Related Macular Degeneration",[26,29,30,31,32,33],"CNV","eyedrop","TKI","Axitinib","Phase2","NOT_YET_RECRUITING","2026-05-20",{"date":37,"type":38},"2026-05-26","ACTUAL",{"date":40,"type":20},"2026-11-01",{"date":42,"type":20},"2027-08-31",{"name":44,"class":45},"SCAI Therapeutics","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100470574","phase-3-pivotal-2-study-of-rgx-314-gene-therapy-in-participants-with-namd-100470574","NCT05407636","Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD","ASCENT","Inclusion Criteria:\n\n1. Age ≥ 50 years and ≤ 89 years\n2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye\n3. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in the study eye previously treated with anti-VEGF\n4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye\n5. Willing and able to provide written, signed informed consent for this study\n6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry\n\nInclusion Criteria (Bilateral Treatment Substudy)\\*:\n\n1. An ETDRS BCVA letter score between ≤ 83 and ≥ 40 in both eyes\n2. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in both eyes\n3. Must be pseudophakic (at least 12 weeks postcataract surgery) in both eyes\n4. Willing and able to provide written, signed informed consent for this study\n5. Newcomers must have active disease in the study eye; crossover participants must have active disease in the eye not treated in the main study\n\nExclusion Criteria:\n\n1. CNV or macular edema in the study eye secondary to any causes other than AMD\n2. Subfoveal fibrosis or atrophy in the study eye\n3. Any condition in the investigator's opinion that could limit VA improvement in the study eye\n4. Advanced glaucoma or history of secondary glaucoma in the study eye\n5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months\n6. History of intraocular surgery in the study eye within 12 weeks prior to randomization\n7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6\n8. Prior treatment with gene therapy\n\nExclusion Criteria (Bilateral Treatment Substudy)\\*:\n\n1. CNV or macular edema in either eye secondary to any causes other than AMD\n2. Subfoveal fibrosis or atrophy in either eye\n3. Any condition in the investigator's opinion that could limit VA improvement in either eye\n4. Advanced glaucoma or history of secondary glaucoma in either eye\n5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months\n6. History of intraocular surgery in either eye within 12 weeks prior to randomization\n7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6.\n8. Prior treatment with gene therapy (\\*) For previously treated crossover participants, criteria apply to the eye not treated in the main study only.\n\nNote: Other inclusion\u002Fexclusion criteria apply","89 Years",{"count":56,"type":20},714,[58],"PHASE3","ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.",[61,62,63,64,65,29],"AMD","nAMD","Wet Age-related Macular Degeneration","wAMD","WetAMD",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,61,86],"Age-Related Macular Degeneration","Neovascular Age-Related Macular Degeneration","Macular Degeneration","Wet Macular Degeneration","Choroidal Neovascularization","Retinal Degeneration","Retinal Diseases","Eye Diseases","Ranibizumab","Aflibercept","Angiogenesis Inhibitors","Angiogenesis Modulating Agents","Growth Substances","Physiological Effects of Drugs","Growth Inhibitors","Antineoplastic Agents","Gene Therapy","Anti-vascular endothelial grown factory therapy","Anti-VEGF therapy","wet AMD","RECRUITING","2026-04-15",{"date":90,"type":38},"2026-04-20",{"date":92,"type":38},"2022-01-13",{"date":94,"type":20},"2027-11",{"name":96,"class":45},"AbbVie",181]